[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341159-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341159-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-potential-and-promise-for-clinical-application-of-adoptive-t-cell-therapy-in-cancer-review","The potential and promise for clinical application of adoptive T cell therapy in cancer - Review","","Adoptive cell therapy has transformed cancer treatment, particularly hematologic malignancies, with T cells as the most widely used effector population. The review contrasts three major approaches—tumor-infiltrating lymphocytes, T cell receptor-transgenic T cells, and chimeric antigen receptor T cells—highlighting their mechanisms of tumor targeting and activation. It details key barriers limiting clinical efficacy, including tumor heterogeneity and antigen escape, poor trafficking and infiltration, immunosuppressive microenvironments, and T cell exhaustion. Strategies to enhance performance, such as multispecific CAR T therapy and immune checkpoint combinations, are summarized, emphasizing continued promise in solid tumors.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-potential-and-promise-for-clinical-application-of-adoptive-t-cell-therapy-in-cancer-review/341159/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-potential-and-promise-for-clinical-application-of-adoptive-t-cell-therapy-in-cancer-review/341159.png","ImageObject",300,407,{"name":42,"@type":43},"Eliana","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are the three main adoptive T cell therapies discussed in the review?","Question",{"text":63,"@type":64},"The review focuses on tumor-infiltrating lymphocytes, T cell receptor-transgenic T cells, and chimeric antigen receptor T cells. Each approach uses a different method to achieve tumor recognition and killing.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do chimeric antigen receptor (CAR) T cells attack tumors without major histocompatibility complex assistance?",{"text":68,"@type":64},"CAR T cells carry genes encoding antigen-recognition structural domains and T cell activation signals into T cells. This enables tumor attack without requiring major histocompatibility complex support.",{"name":70,"@type":61,"acceptedAnswer":71},"Which barriers most affect the clinical efficacy of adoptive T cell therapy?",{"text":72,"@type":64},"Reported barriers include tumor heterogeneity and antigen loss, limited trafficking and infiltration, immunosuppressive tumor microenvironment, and T cell exhaustion.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341159,1790463184,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Li et al. Journal of Translational Medicine (2024) 22:413  \n[https://doi.org/10.1186/s12967-024-05206-7](https://doi.org/10.1186/s12967-024-05206-7)  \nJournal of Translational Medicine  \n REVIEW Open Access  \nThe potential and promise for clinical  \napplication of adoptive T cell therapy in cancer  \nYinqi Li1†, Yeteng Zheng1†, Taiqing Liu 1, Chuanyun Liao 1, Guobo Shen2* and Zhiyao He1,3*  \nAbstract  \nAdoptive cell therapy has revolutionized cancer treatment, especially for hematologic malignancies. T cells are the most extensively utilized cells in adoptive cell therapy. Currently, tumor-infiltrating lymphocytes, T cell receptortransgenic T cells and chimeric antigen receptor T cells are the three main adoptive T cell therapies. Tumor-infiltrating lymphocytes kill tumors by reinfusing enlarged lymphocytes that naturally target tumor-specific antigens into the patient. T cell receptor-transgenic T cells have the ability to specifically destroy tumor cells via the precise recognition of exogenous T cell receptors with major histocompatibility complex. Chimeric antigen receptor T cells transfer genes with specific antigen recognition structural domains and T cell activation signals into T cells, allowingT cells to attack tumors without the assistance of major histocompatibility complex. Many barriers have been demonstrated to affect the clinical efficacy of adoptive T cell therapy, such as tumor heterogeneity and antigen loss, hard trafficking and infiltration, immunosuppressive tumor microenvironment and T cell exhaustion. Several strategies to improve the efficacy of adoptive T cell therapy have been explored, including multispecific chimeric antigen receptor T cell therapy, combination with immune checkpoint blockade, targeting the immunosuppressive tumor microenvironment, etc. In this review, we will summarize the current status and clinical application, followed by major bottlenecks in adoptive T cell therapy. In addition, we will discuss the promising strategies to improve adoptive T cell therapy. Adoptive T cell therapy will result in even more incredible advancements in solid tumors if the aforementioned problems can be handled.  \nKeywords Immunotherapy, Adoptive cell therapy, Chimeric antigen receptor, T cell receptor, Tumor-infiltrating lymphocytes  \n†Yinqi Li andYeteng Zheng have contributed equally to this work.  \n*Correspondence: Guobo Shen [shenguobo@126.com](shenguobo@126.com)[ ](shenguobo@126.com)Zhiyao He[heyaode@163.com](heyaode@163.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[. The Creative Commons Public Domain Dedication waiver (](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[http://creativeco](http://creativeco)[mmons.org/publicdomain/zero/1.0/](mmons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated in a credit line to the data.  \nLi etal. Journal of Translational Medicine (2024) 22:413 Page 2 of 21  \nGraphi","cbCaimr5YrwK7eW1","https://ap.wps.com/l/cbCaimr5YrwK7eW1","pdf",1739133,21,"English","# Background\n## Immunotherapy and immune checkpoint blockade\n## Rationale for adoptive cell therapy\n# Tumor-infiltrating lymphocytes and CAR T cells\n## Clinical observations in melanoma\n## CAR T outcomes in CD19+ malignancies\n# T cell receptor engineering and next steps\n## TCR transfer enabling targeted recognition\n## Transition to T cell-based ACT","[{\"question\":\"What are the three main adoptive T cell therapies discussed in the review?\",\"answer\":\"The review focuses on tumor-infiltrating lymphocytes, T cell receptor-transgenic T cells, and chimeric antigen receptor T cells. Each approach uses a different method to achieve tumor recognition and killing.\"},{\"question\":\"How do chimeric antigen receptor (CAR) T cells attack tumors without major histocompatibility complex assistance?\",\"answer\":\"CAR T cells carry genes encoding antigen-recognition structural domains and T cell activation signals into T cells. This enables tumor attack without requiring major histocompatibility complex support.\"},{\"question\":\"Which barriers most affect the clinical efficacy of adoptive T cell therapy?\",\"answer\":\"Reported barriers include tumor heterogeneity and antigen loss, limited trafficking and infiltration, immunosuppressive tumor microenvironment, and T cell exhaustion.\"}]","The potential and promise for clinical application of adoptive T cell therapy in cancer - Review | PDF",1790040602,53,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7926cd5a37d14f6c5d297f189cf8063b.webp",983,1305,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc250ff2b181b4384b66073061ef27d2.webp",982,1304,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6bc085ab993e577e3b257b374e4e1be0.webp",981,1303,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/355b92a0cd3b1f0ed142c401fab50098.webp",980,1301]